Cycloalkylamines as monoamine reuptake inhibitors

Patent metadata

Field	Value
Publication number	US-9868718-B2
Application number	US-201414502532-A
Country	US
Kind code	B2
Filing date	Sep 30, 2014
Priority date	Jan 6, 2006
Publication date	Jan 16, 2018
Grant date	Jan 16, 2018

Abstract

The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.

First claim

What is claimed is:

1. A compound, wherein the compound is:

or any salt form, solvate, enantiomer, diastereomer, racemic mixture, enantiomerically enriched mixture, and enantiomerically pure form thereof.

2. A compound, wherein the compound is:

or any salt form, solvate, enantiomer, diastereomer, racemic mixture, enantiomerically enriched mixture, and enantiomerically pure form thereof.

Assignees

• Sunovion Pharmaceuticals Inc

Inventors

• Shao Liming
• Wang Fengjiang
• Malcolm Scott Christopher
• Hewitt Michael Charles
• Bush Larry R
• Ma Jianguo
• Varney Mark A
• Campbell Una
• Engel Sharon Rae
• Hardy Larry Wendell
• Koch Patrick
• Campbell John E

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P25/16

  Anti-Parkinson drugs · CPC title

• A61P25/24

  Antidepressants · CPC title

• A61P25/22

  Anxiolytics · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title